Gc Biopharma
Gc Biopharma, officially known as Green Cross Biopharma, is a leading biopharmaceutical company headquartered in South Korea (KR). Established in 1967, the company has made significant strides in the biopharmaceutical industry, focusing on the development and production of innovative therapies, particularly in the fields of immunology and infectious diseases. With a strong presence in Asia and expanding operations globally, Gc Biopharma is renowned for its core products, including plasma-derived therapies and vaccines. These offerings are distinguished by their high quality and efficacy, positioning the company as a trusted provider in the healthcare sector. Notable achievements include its commitment to research and development, which has propelled Gc Biopharma to a prominent market position, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Gc Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gc Biopharma's score of 21 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gc Biopharma's reported carbon emissions
In 2023, Gc Biopharma, headquartered in South Korea (KR), reported a greenhouse gas emissions intensity of approximately 0.0005607 kg CO2e per unit of revenue. This figure reflects the company's commitment to monitoring its carbon footprint, although specific total emissions data for Scope 1, 2, and 3 are not disclosed. Over the past few years, Gc Biopharma has shown a slight decrease in emissions intensity, with values of about 0.0005825 kg CO2e in 2021 and 0.000537 kg CO2e in 2022. However, the company has not set specific reduction targets or disclosed any significant climate pledges as part of its sustainability strategy. While Gc Biopharma is actively tracking its emissions, the absence of detailed emissions data and reduction initiatives indicates an opportunity for the company to enhance its climate commitments and transparency in line with industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gc Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
